Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_3
2
67%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 32 (66.7%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

NCT02439216
completedphase_3

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03703882
terminatedphase_3

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03917719

Clinical Trials (3)

Showing 3 of 3 trials
NCT02439216Phase 1

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

Completed
NCT03703882Phase 3

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

Completed
NCT03917719Phase 3

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3